US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
SNDK
$1,704.16
▼-0.92%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
SNDK
$1,704.16
▼-0.92%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Deciphera Pharmaceuticals, Inc.
< Previous
1
2
Next >
U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
August 15, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
July 18, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
June 03, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
April 29, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 09, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
February 27, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
February 06, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
February 01, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
January 18, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
January 08, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
January 05, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
November 29, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
November 07, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
October 30, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
October 30, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
August 09, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
August 03, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
August 02, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
May 25, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
May 23, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
May 08, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
May 03, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
April 26, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
April 19, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
March 14, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
< Previous
1
2
Next >
